Skip to main content
SpringerLink
Log in

The Defined Daily Dose as a Tool in Pharmacoeconomics

Advantages and Limitations

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Drummond M, Brandt A, Luce B, et al. Standardising methodologies for economic evaluation in health care. Practice, problems and potential. Int J Technol Assess Health Care 1993; 9 (1): 26–36

    Article  PubMed  CAS  Google Scholar 

  2. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic appraisal of health care programmes. Oxford: Oxford University Press, 1987

    Google Scholar 

  3. Bootman JL, Larson LN, McGhan WF, et al. Pharmacoeconomics research and clinical trials: concepts and issues. PharmacoEconomics 1989; 23: 693–7

    CAS  Google Scholar 

  4. Diamond GA, Denton TA, Matloff JM. Fee-for-benefit: a strategy to improve the quality of health care and control costs through reimbursement incentives. J Am Coll Cardiol 1993; 22: 343–52

    Article  PubMed  CAS  Google Scholar 

  5. Guidelines for DDD. Oslo: WHO ColIaborating Centre for Drug Statistics Methodology, 1991

  6. Anatomical Therapeutic Chemical (ATC) classification index, including Defined Daily Doses (DDDs) for plain substances. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 1993

  7. Lunde PKM, Baksaas I. Epidemiology of drug utilisation: basic concepts and methodology. Acta Med Scand 1987; Suppl. 721: 7–11

    Google Scholar 

  8. WHO. The selection and use of essential drugs. WHO Tech Rep Ser 615. Geneva: WHO, 1977

  9. WHO. The selection and use of essential drugs. WHO Tech Rep Ser 641. Geneva: WHO, 1979

  10. WHO. The selection and use of essential drugs. WHO Tech Rep Ser 685. Geneva: WHO, 1983

  11. WHO. The selection and use of essential drugs. WHO Tech Rep Ser 722. Geneva: WHO, 1985

  12. Maxwell M, Heaney D, Howie JGR, et al. General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method. BMJ 1993; 307: 1190–4

    Article  PubMed  CAS  Google Scholar 

  13. Szuba TJ, Westerholm B. Studies on drug utilization: bilateral case study in Poland and Sweden. Soc Sci Med 1989; 29: 1363–6

    Article  PubMed  CAS  Google Scholar 

  14. Hopley PJ, Piercy J. Information on the public health from PACT data. Pharm J 1991 Oct 12; 6657 Suppl.: R34

    Google Scholar 

  15. Clarke KW, Gray D, Hampton JR. Defined daily doses: insensitive in determining disease prevalence. Pharm J 1994; 252: 334–5

    Google Scholar 

  16. Papoz L and the EURODIAB Subarea C Study Group. Utilisation of drug sales data for the epidemiology of chronic diseases: the example of diabetes. Epidemiology 1993; 4: 421–7

    Article  PubMed  CAS  Google Scholar 

  17. Jolicoeur LM, Jones-Grizzle AJ, Boyer JG. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm 1992; 49: 1741–7

    PubMed  CAS  Google Scholar 

  18. British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. London: Pharmaceutical Press, 1994

    Google Scholar 

  19. Illingworth DR, Erkenlens DW, Keller U, et al. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin and simvastatin [correspondence]. Lancet 1994; 343: 1554

    Article  PubMed  CAS  Google Scholar 

  20. Malcolm LA, Higgins CS. General practitioner prescribing rated and costs. N Z Med J 1981; 93: 301–3

    PubMed  CAS  Google Scholar 

  21. Maxwell M, Heaney D, Howie JGR, et al. General practice fundholding: observations on prescribing patterns and costs using the defined daily dose method. BMJ 1993; 307: 1190–4

    Article  PubMed  CAS  Google Scholar 

  22. Brenner G. Methods to assess health economics aspects of drug utilisation. Acta Med Scand 1987; Suppl. 721: 31–5

    Google Scholar 

  23. Boethius G. Approaches to assessing the rationality of drug usage in a developed country. Acta Med Scand 1989; Suppl. 721: 21–6

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Cardiothoracic Centre, Thomas Drive, Liverpool, L14 3PE, England

    Karen W. Clarke

  2. Cardiovascular Medicine, University Hospital, Nottingham, England

    David Gray

Authors
  1. Karen W. Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clarke, K.W., Gray, D. The Defined Daily Dose as a Tool in Pharmacoeconomics. Pharmacoeconomics 7, 280–283 (1995). https://doi.org/10.2165/00019053-199507040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199507040-00002

Keywords

Search

Navigation